nach oben

Erschienen in:

22.01.2022 | Original Article

Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer

verfasst von: Tuo Deng, Jialiang Li, Bangjie He, Bo Chen, Fangting Liu, Ziyan Chen, Jiuyi Zheng, Zhehao Shi, Tan Zhang, Liming Deng, Haitao Yu, Jinhuan Yang, Lijun Wu, Yunfeng Shan, Zhengping Yu, Xiaolei Chen, Yi Wang, Gang Chen

Erschienen in: Hepatology International | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary liver cancer has high mortality and morbidity worldwide. However, the characteristic of gut microbiota profile and its correlation with inflammation status in liver cancer patients remains largely unknown, and a gut microbiome-based diagnostic model for liver cancer is still absent.

Methods

Here, we provided a comprehensive analysis based on fecal 16S rRNA sequencing and clinical data in a cohort consisting of 40 healthy volunteers, 143 hepatocellular carcinoma (HCC) patients, and 46 cholangiocarcinoma (CCA) patients.

Results

Our results indicated a distinct shift of gut microbiota composition between two primary liver cancer types and compared with healthy volunteers. Based on the diversity constitute of gut microbiome taxonomy and random forest algorithm, eight genera with mean abundance above 0.1% were selected to construct the classification model with half of the randomly selected cohort. Based on this signature, high diagnostic accuracy in the validation cohort to classify liver cancer types (AUC = 0.989, 0.967, 0.920 for Control, HCC, CCA separately) was achieved. Further analysis showed increased Gram-negative bacteria and elevated inflammatory response markers in CCA group versus HCC group. The correlation analysis between inflammatory response markers and composition of gut microbiome revealed decreased potentially beneficial genus and increased opportunistic pathogens positively correlated with adverse prognostic inflammatory response markers.

Conclusion

Generally, our study established the gut microbiome-based signature for liver cancer prediction and screening and revealed that gut microbiome characteristic in primary liver cancer was correlated with adverse inflammatory response markers in liver cancer.

Nur mit Berechtigung zugänglich

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 71, 209–249, doi:https://doi.org/10.3322/caac.21660 (2021).

Zheng, R. et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 30, 571–579, doi:https://doi.org/10.21147/j.issn.1000-9604.2018.06.01 (2018).

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–761. https://doi.org/10.1053/j.gastro.2016.11.048CrossRefPubMed

Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med. 2015;5: a021535. https://doi.org/10.1101/cshperspect.a021535CrossRefPubMedPubMedCentral

Zeng H, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer. 2015;136:1921–1930. https://doi.org/10.1002/ijc.29227CrossRefPubMed

Yang, J. & Heimbach, J. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ (Clinical research ed.) 371, m3544, doi:https://doi.org/10.1136/bmj.m3544 (2020).

Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035–2044. https://doi.org/10.1136/gutjnl-2016-312729CrossRefPubMed

Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev. 2017;279:70–89. https://doi.org/10.1111/imr.12567CrossRefPubMedPubMedCentral

Benakis C, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med. 2016;22:516–523. https://doi.org/10.1038/nm.4068CrossRefPubMedPubMedCentral

10.

Qin J, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. https://doi.org/10.1038/nature11450CrossRefPubMed

11.

Yu J, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–78. https://doi.org/10.1136/gutjnl-2015-309800CrossRefPubMed

12.

Zheng Y, et al. Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes. 2020;11:1030–1042. https://doi.org/10.1080/19490976.2020.1737487CrossRefPubMedPubMedCentral

13.

Jones RM, Neish AS. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol. 2021;16:251–275. https://doi.org/10.1146/annurev-pathol-030320-095722CrossRefPubMed

14.

Tripathi A, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397–411. https://doi.org/10.1038/s41575-018-0011-zCrossRefPubMedPubMedCentral

15.

Man SM. Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol Hepatol. 2018;15:721–737. https://doi.org/10.1038/s41575-018-0054-1CrossRefPubMedPubMedCentral

16.

Logue JB, et al. Experimental insights into the importance of aquatic bacterial community composition to the degradation of dissolved organic matter. ISME J. 2016;10:533–545. https://doi.org/10.1038/ismej.2015.131CrossRefPubMed

17.

Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011 17, 3, doi:https://doi.org/10.14806/ej.17.1.200 (2011)

18.

Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics (Oxford, England). 2011;27:2957–2963. https://doi.org/10.1093/bioinformatics/btr507CrossRef

19.

Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4: e2584. https://doi.org/10.7717/peerj.2584CrossRefPubMedPubMedCentral

20.

Callahan BJ, et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–583. https://doi.org/10.1038/nmeth.3869CrossRefPubMedPubMedCentral

21.

Bolyen E, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852–857. https://doi.org/10.1038/s41587-019-0209-9CrossRefPubMedPubMedCentral

22.

Segata N, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60. https://doi.org/10.1186/gb-2011-12-6-r60CrossRefPubMedPubMedCentral

23.

Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics (Oxford, England). 2014;30:3123–3124. https://doi.org/10.1093/bioinformatics/btu494CrossRef

24.

Ward, T. et al. BugBase predicts organism-level microbiome phenotypes. bioRxiv, 133462, doi:https://doi.org/10.1101/133462 (2017).

25.

Ren Z, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014–1023. https://doi.org/10.1136/gutjnl-2017-315084CrossRefPubMed

26.

Jia, X. et al. Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma. Hepatology (Baltimore, Md.) 71, 893–906, doi:https://doi.org/10.1002/hep.30852 (2020).

27.

Lu, H. et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microbial ecology 61, 693–703, doi:https://doi.org/10.1007/s00248-010-9801-8 (2011).

28.

Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691–701. https://doi.org/10.1038/nrgastro.2010.172CrossRefPubMed

29.

Mariat D, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123. https://doi.org/10.1186/1471-2180-9-123CrossRefPubMedPubMedCentral

30.

Magne, F. et al. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients 12, doi:https://doi.org/10.3390/nu12051474 (2020).

31.

Grigor'eva, I. N. Gallstone Disease, Obesity and the Firmicutes/Bacteroidetes Ratio as a Possible Biomarker of Gut Dysbiosis. Journal of personalized medicine 11, https://doi.org/10.3390/jpm11010013 (2020).

32.

Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30:332–338. https://doi.org/10.1097/mog.0000000000000057CrossRefPubMedPubMedCentral

33.

Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731–16736. https://doi.org/10.1073/pnas.0804812105CrossRefPubMedPubMedCentral

34.

Machiels K, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283. https://doi.org/10.1136/gutjnl-2013-304833CrossRefPubMed

35.

Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15:111–128. https://doi.org/10.1038/nrgastro.2017.119CrossRefPubMed

36.

Qin N, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64. https://doi.org/10.1038/nature13568CrossRefPubMed

37.

Shacter, E. & Weitzman, S. A. Chronic inflammation and cancer. Oncology (Williston Park, N.Y.) 16, 217–226, 229; discussion 230–212 (2002).

38.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentral

39.

Dapito DH, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–516. https://doi.org/10.1016/j.ccr.2012.02.007CrossRefPubMedPubMedCentral

40.

Yu, L. X. et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology (Baltimore, Md.) 52, 1322–1333, doi:https://doi.org/10.1002/hep.23845 (2010).

41.

Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121:977–990. https://doi.org/10.1016/j.cell.2005.04.014CrossRefPubMed

42.

Szabo, G., Dolganiuc, A. & Mandrekar, P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology (Baltimore, Md.) 44, 287–298, doi:https://doi.org/10.1002/hep.21308 (2006).

43.

Miyahara Y, Takashi S, Shimizu Y, Ohtsuka M. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer. World journal of surgical oncology. 2020;18:78. https://doi.org/10.1186/s12957-020-01847-2CrossRefPubMedPubMedCentral

44.

Wang C, et al. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int. 2020;40:229–239. https://doi.org/10.1111/liv.14281CrossRefPubMed

45.

Wei Y, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020;69:569–577. https://doi.org/10.1136/gutjnl-2018-317836CrossRefPubMed

46.

Matera G, et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopolysaccharide. Clin Vaccine Immunol. 2009;16:1804–1809. https://doi.org/10.1128/cvi.00310-09CrossRefPubMedPubMedCentral

47.

Lamping N, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Investig. 1998;101:2065–2071. https://doi.org/10.1172/jci2338CrossRefPubMedPubMedCentral

48.

Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci USA. 1999;96:9833–9838. https://doi.org/10.1073/pnas.96.17.9833CrossRefPubMedPubMedCentral

49.

Pushalkar S, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403–416. https://doi.org/10.1158/2159-8290.cd-17-1134CrossRefPubMedPubMedCentral

50.

Kosumi K, et al. The Amount of Bifidobacterium genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. Am J Pathol. 2018;188:2839–2852. https://doi.org/10.1016/j.ajpath.2018.08.015CrossRefPubMedPubMedCentral

Titel: Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer
verfasst von: Tuo Deng
Jialiang Li
Bangjie He
Bo Chen
Fangting Liu
Ziyan Chen
Jiuyi Zheng
Zhehao Shi
Tan Zhang
Liming Deng
Haitao Yu
Jinhuan Yang
Lijun Wu
Yunfeng Shan
Zhengping Yu
Xiaolei Chen
Yi Wang
Gang Chen
Publikationsdatum: 22.01.2022
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 1/2022
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10279-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies

Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria